Chemomab
Tel Aviv · Founded 2011 · 20 employees on LinkedIn · 2 known investors
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis. The company focuses on anti-fibrotic and anti-inflammatory treatments for patients with fibrotic diseases.
Founders & leadership
Chemomab was founded in 2011 by Adi Mor and Adi Mor George.
AM
Adi MorinCo-founder · CEO & CSO
AM
Adi Mor GeorgeCo-founder
JQ
Jill QuigleyinMember of the Board of Directors2022–2026
SF
Sigal FattalinChief Financial Officer
MF
Matthew FrankelinChief Medical Officer (CMO)2022–2025
AA
Arnon AharoninChief Medical Officer2016–2022
SF
Sigal FatalExecutive
Board
ND
Nissim DarvishBoard director
SP
NH
Neil Harris CohenBoard director
AC
Alan Charles MosesBoard director
CN
Claude NicaiseBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$55.4M disclosed across 2 of 3 rounds · 2021–2026
▶$10MraisedAug 2024 · 10 investors · BiotechnologyRule 506(b)
▶$10MraisedAug 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neil Harris CohenDirector
- Jill QuigleyDirector
- Sigal FattalExecutive Officer
- Adi MorExecutive Officer, Director
- Alan Charles MosesDirector
- Matthew FrankelExecutive Officer
- Claude NicaiseDirector
- Nissim DarvishDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $400K
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Jul 2024
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$45.4MraisedMar 2021 · 26 investors · BiotechnologyRule 506(b)
▶$45.4MraisedMar 2021 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adi Mor GeorgeExecutive Officer, Director
- Arnon AharonExecutive Officer
- Neil Harris CohenDirector
- Joel Michael MarylesDirector
- Nissim DarvishDirector
- Claude NicaiseDirector
- Sigal FatalExecutive Officer
- Stephen P SquintoDirector
- Moses Charles AlanDirector
- Offering amount
- $45.4M
- Amount sold
- $45.4M
- Sales commissions
- $1.6M
- Placement agents
- Oppenheimer & Co. Inc.
- First sale
- Mar 2021
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Chemomab do?
- Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis. The company focuses on anti-fibrotic and anti-inflammatory treatments for patients with fibrotic diseases.
- Who founded Chemomab?
- Chemomab was founded by Adi Mor, Adi Mor George in 2011.
- Who are Chemomab's investors?
- Chemomab's investors include Altium Capital, OrbiMed.
- How much funding has Chemomab raised?
- Chemomab has disclosed $55.4M raised across 2 of its 3 known rounds.
- Where is Chemomab headquartered?
- Chemomab is headquartered in Tel Aviv.